Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has received two notices of allowance from USPTO for BL-1021, an orally available small molecule for treating neuropathic pain.
Subscribe to our email newsletter
The first notice of allowance is issued for patent application claiming BL-1021’s composition. Once issued, the patent will be valid until at least September 2022.
The second one is issued for application claiming the use of BL-1021 for the treatment of pain, which will be valid until at least January 2028 when issued.
BioLineRx CEO Kinneret Savitsky said BL-1021 may present an improved treatment for such patients, greatly improving their quality of life.
Additional patents claiming BL-1021’s composition are granted or pending in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico and India.
Additional patents claiming the use of BL-1021 as pain therapy are pending in Australia, Canada, China, Europe, Israel, Japan, Korea, Mexico and India.